GSK3β and cyclin D1 expression predicts outcome in early breast cancer patients

Breast Cancer Research and Treatment

Volumn 136, Issue 1, 2012, Pages 161-168

  Quintayo, Mary Anne ^a,b   Munro, Alison F ^a   Thomas, Jeremy ^c   Kunkler, Ian H ^c   Jack, Wilma ^c   Kerr, Gillian R ^c   Dixon, J M ^d   Chetty, Udi ^c   Bartlett, John M S ^a,b  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b ONTARIO INSTITUTE FOR CANCER RESEARCH   (Canada)

^c Edinburgh Cancer Centre   (United Kingdom)

^d Breakthrough Research Unit   (United Kingdom)

Author keywords

CCND1; Cyclin D1; GSK3 ; p GSK3

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLIN D1; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; GLYCOGEN SYNTHASE KINASE 3BETA; PROGESTERONE RECEPTOR; TAMOXIFEN;

ADULT; ARTICLE; BREAST CANCER; CANCER PATIENT; CANCER PROGNOSIS; CANCER SPECIFIC SURVIVAL; CANCER TISSUE; CCND1 GENE; COHORT ANALYSIS; DISEASE ASSOCIATION; DISTANT RELAPSE FREE SURVIVAL; EARLY CANCER; ENZYME PHOSPHORYLATION; GENE; GENE AMPLIFICATION; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PARTIAL MASTECTOMY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; SURVIVAL; SURVIVAL TIME; TISSUE MICROARRAY; UNITED KINGDOM;

AGED; BREAST NEOPLASMS; CYCLIN D1; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GLYCOGEN SYNTHASE KINASE 3; HUMANS; MIDDLE AGED; PHOSPHATIDYLINOSITOL 3-KINASES; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; TAMOXIFEN; TISSUE ARRAY ANALYSIS; TREATMENT OUTCOME;

EID: 84867878902     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-012-2229-8     Document Type: Article

References (24)

1. Embi N, Rylatt DB, Cohen P (1980) Glycogen synthase kinase-3 from rabbit skeletal muscle. Eur J Biochem 107(2):519-527
2. Woodgett JR, Cohen P (1984) Multisite phosphorylation of glycogen synthase. Molecular basis for the substrate specificity of glycogen synthase kinase-3 and casein kinase-II (glycogen synthase kinase-5). Biochim Biophys Acta 788(3):339-347
3. Cohen P, Alessi DR, Cross DAE (1997) PDK1, one of the missing links in insulin signal transduction? FEBS Lett 410(1):3-10
4. Pap M, Cooper GM (1998) Role of glycogen synthase kinase-3 in the phosphatidylinositol 3-kinase/Akt cell survival pathway. J Biol Chem 273(32):19929-19932
5. Doble BW, Woodgett JR (2003) GSK-3: tricks of the trade for a multi-tasking kinase. J Cell Sci 116(7):1175-1186
6. Shimura T, Kakuda S, Ochiai Y et al (2010) Acquired radioresistance of human tumor cells by DNA-PK/AKT/GSK3[beta]-mediated cyclin D1 overexpression. Oncogene 29(34):4826-4837
7. Roy PG, Thompson AM (2006) Cyclin D1 and breast cancer. Breast 15(6):718-727
8. Goto H, Kawano K, Kobayashi I et al (2002) Expression of cyclin D1 and GSK-3beta and their predictive value of prognosis in squamous cell carcinomas of the tongue. Oral Oncol 38(6):549-556
9. Thomas JS, Kerr GR, Jack WJL et al (2009) Histological grading of invasive breast carcinoma-a simplification of existing methods in a large conservation series with long-term follow-up. Histopathology 55(6):724-731
10. Kunkler IH, Kerr GR, Thomas JS et al (2011) Impact of screening and risk factors for local recurrence and survival after conservative surgery and radiotherapy for early breast cancer: results from a large series with long-term follow-up. Int J Radiat Oncol Biol Phys
11. Leyland-Jones BR, Ambrosone CB, Bartlett J et al (2008) Recommendations for collection and handling of specimens from group breast cancer clinical trials. J Clin Oncol 26(34):5638-5644
12. Kirkegaard T, McGlynn LM, Campbell FM et al (2007) Amplified in breast cancer 1 in human epidermal growth factor receptor positive tumors of tamoxifen-treated breast cancer patients. Clin Cancer Res 13(5):1405-1411
13. Kirkegaard T, Edwards J, Tovey S et al (2006) Observer variation in immunohistochemical analysis of protein expression, time for a change? Histopathology 48(7):787-794
14. Bartlett JMS, Going JJ, Mallon EA et al (2001) Evaluating HER2 amplification and overexpression in breast cancer. J Pathol 195(4):422-428
15. Ellis IO, Bartlett J, Dowsett M et al (2004) Best practice No 176. J Clin Pathol 57(3):233-237
16. Zheng Hc, Xu Xy, Xia P et al (2010) Involvement of inactive GSK3beta overexpression in tumorigenesis and progression of gastric carcinomas. Hum Pathol 41(9):1255-1264
17. Luo J (2009) Glycogen synthase kinase 3beta (GSK3beta) in tumorigenesis and cancer chemotherapy. Cancer Lett 273(2):194-200
18. Armanious H, Deschenes J, Gelebart P et al (2010) Clinical and biological significance of GSK-3beta inactivation in breast cancer - an immunohistochemical study. Hum Pathol 41(12):1657-1663
19. Huac Z, Hiro S, Shin M et al (2007) Phosphorylated GSK3beta Ser9 and EGFR are good prognostic factors for lung carcinomas. Anticancer Res 27(5b):3561-3569
20. Reis-Filho JS, Savage K, Lambros MBK et al (2006) Cyclin D1 protein overexpression and CCND1 amplification in breast carcinomas: an immunohistochemical and chromogenic in situ hybridisation analysis. Mod Pathol 19(7):999-1009
21. Gillett C, Smith P, Gregory W et al (1996) Cyclin D1 and prognosis in human breast cancer. Int J Cancer 69(2):92-99
22. Bilalovic N, Vranic S, Basic H et al (2005) Immunohistochemical evaluation of cyclin D1 in breast cancer. Croat Med J 46(3):382-388
23. Oyama T, Kashiwabara K, Yoshimoto K et al (1998) Frequent overexpression of the cyclin D1 oncogene in invasive lobular carcinoma of the breast. Cancer Res 58(13):2876-2880
24. Staal FJT, Clevers HC (2005) WNT signalling and haematopoiesis: a WNT-WNT situation. Nat Rev Immunol 5(1):21-30